TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07209462: Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

Sponsor: Mirum Pharmaceuticals, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$2,191,200

Rescue Site Savings

+$1,460,800

Unlock Full NCT07209462 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07209462 Rescue Dossier →